Research Analysts Offer Predictions for LENZ Q3 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings estimates for shares of LENZ Therapeutics in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($0.80) for the quarter, up from their previous forecast of ($0.87). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($0.45) EPS.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02.

Other research analysts have also issued research reports about the company. Piper Sandler began coverage on LENZ Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $51.00 price target for the company. Citigroup increased their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, May 8th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $46.60.

LENZ Therapeutics Trading Up 0.1%

Shares of NASDAQ:LENZ traded up $0.03 during trading on Monday, reaching $27.66. 65,522 shares of the company traded hands, compared to its average volume of 185,998. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93. The firm has a market capitalization of $778.52 million, a price-to-earnings ratio of -15.63 and a beta of 0.41. The business's fifty day moving average is $24.90 and its 200-day moving average is $27.34.

Hedge Funds Weigh In On LENZ Therapeutics

A number of large investors have recently made changes to their positions in the company. Delta Investment Management LLC lifted its holdings in LENZ Therapeutics by 24.7% during the 1st quarter. Delta Investment Management LLC now owns 24,001 shares of the company's stock valued at $617,000 after buying an additional 4,760 shares in the last quarter. AlphaQuest LLC bought a new position in shares of LENZ Therapeutics during the 1st quarter worth approximately $168,000. Wellington Management Group LLP boosted its holdings in shares of LENZ Therapeutics by 8.1% in the 1st quarter. Wellington Management Group LLP now owns 30,488 shares of the company's stock valued at $784,000 after acquiring an additional 2,272 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of LENZ Therapeutics in the first quarter worth $1,276,000. Finally, Nuveen LLC acquired a new stake in shares of LENZ Therapeutics in the first quarter worth $1,724,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.